Jennifer Davagian Ensign, Founder & CEO of Cristcot Inc. today announced that Sephure, a first-of-its-kind disposable suppository applicator, is now available to the millions of people who require suppository medication therapy. Although billions of suppositories are sold around the world each year, there is no standard of care for their administration. Sephure will make its debut at Digestive Disease Week in Chicago May 3-6th at booth #752.
Necessity was the mother of invention for Ensign who was diagnosed with Inflammatory Bowel Disease more than 20 years ago and lived with infrequent flares. Each dose took 30-45 minutes lying in the prone position, inserting the suppository with her finger and resisting the urgency to release the medication. Upon standing, she needed to wear protective undergarments because the medicine leaked outside the body. Within a few months the regimen became too burdensome for Ensign and she abandoned her treatment.
A serious health scare and a desire for a better quality of life led Ensign to create the device. She taught herself plastic and silicone molding to create a prototype in 2007. Today, with two patents and IP around the globe under her belt, Sephure has CE marking and is FDA cleared for marketing and distribution in the US.
"At first it was difficult talking about something so private in a public forum," Ensign said. "By telling my story I hope to create a new standard of care and in the process, improve the quality of life of others who struggle with the difficulties of suppository treatment."
Ensign also plans to give back to the Crohn's and Colitis Foundation of America (CCFA) and announced that one cent from every Sephure® applicator ordered through its e-commerce website, www.sephure.com, will be donated to the Crohn's and Colitis Foundation of America to help fund research to cure Inflammatory Bowel Disease.